Its GLP-1 medicines are just one reason why it could threaten Novo Nordisk.
Even if you might not fully understand what it means in a technical sense, you’ve probably heard of Novo Nordisk’s (NVO 0.07%) medicines like Ozempic and Wegovy. These drugs have been tremendously helpful for people struggling with obesity and type 2 diabetes, respectively.
The underlying compound, called semaglutide, work by targeting the GLP-1 receptor in the human body. And while GLP-1-targeted therapies are…
Read More…
Source: https://www.fool.com/investing/2024/08/25/this-glp-1-biotech-stock-could-give-novo-nordisk-a/